NO20066056L - Behandling med Gemcitabin og en EGFR-inhibitor - Google Patents
Behandling med Gemcitabin og en EGFR-inhibitorInfo
- Publication number
- NO20066056L NO20066056L NO20066056A NO20066056A NO20066056L NO 20066056 L NO20066056 L NO 20066056L NO 20066056 A NO20066056 A NO 20066056A NO 20066056 A NO20066056 A NO 20066056A NO 20066056 L NO20066056 L NO 20066056L
- Authority
- NO
- Norway
- Prior art keywords
- gemcitabine
- kinase inhibitor
- treatment
- egfr kinase
- egfr inhibitor
- Prior art date
Links
- 229940121647 egfr inhibitor Drugs 0.000 title abstract 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title abstract 3
- 229960005277 gemcitabine Drugs 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 229940120982 tarceva Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57654104P | 2004-06-03 | 2004-06-03 | |
| PCT/EP2005/005735 WO2005117887A1 (en) | 2004-06-03 | 2005-05-27 | Treatment with gemcitabine and an egfr-inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20066056L true NO20066056L (no) | 2007-01-25 |
Family
ID=34970803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20066056A NO20066056L (no) | 2004-06-03 | 2006-12-28 | Behandling med Gemcitabin og en EGFR-inhibitor |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20050272688A1 (pt) |
| EP (1) | EP1755608A1 (pt) |
| JP (1) | JP2008501652A (pt) |
| KR (1) | KR100986945B1 (pt) |
| CN (1) | CN1960732A (pt) |
| AU (1) | AU2005249205A1 (pt) |
| BR (1) | BRPI0511760A (pt) |
| CA (1) | CA2567836A1 (pt) |
| IL (1) | IL179525A0 (pt) |
| MX (1) | MXPA06014015A (pt) |
| NO (1) | NO20066056L (pt) |
| NZ (1) | NZ551406A (pt) |
| RU (1) | RU2006146619A (pt) |
| WO (1) | WO2005117887A1 (pt) |
| ZA (1) | ZA200610049B (pt) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE419239T1 (de) | 2000-10-20 | 2009-01-15 | Eisai R&D Man Co Ltd | Verfahren zur herstellung von 4-phenoxy chinolin derivaten |
| JPWO2004080462A1 (ja) | 2003-03-10 | 2006-06-08 | エーザイ株式会社 | ｃ−Ｋｉｔキナーゼ阻害剤 |
| CN101337930B (zh) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
| NZ551355A (en) * | 2004-06-03 | 2009-09-25 | Hoffmann La Roche | Treatment of cancer with irinotecan (CPT-11) and erlotinib |
| GT200500155A (es) * | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
| JP4834553B2 (ja) | 2004-09-17 | 2011-12-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
| US20060084675A1 (en) * | 2004-10-18 | 2006-04-20 | Thomas Efferth | Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor |
| NZ595313A (en) * | 2005-02-18 | 2013-03-28 | Abraxis Bioscience Llc | The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
| JPWO2007052849A1 (ja) * | 2005-11-07 | 2009-04-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用 |
| WO2007061127A1 (ja) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | 多発性骨髄腫に対する抗腫瘍剤 |
| WO2007106503A2 (en) * | 2006-03-13 | 2007-09-20 | Osi Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
| RU2448708C3 (ru) | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
| WO2007146226A2 (en) * | 2006-06-09 | 2007-12-21 | Osi Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
| US20070286864A1 (en) * | 2006-06-09 | 2007-12-13 | Buck Elizabeth A | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors |
| EP2044939A1 (en) * | 2006-06-29 | 2009-04-08 | Eisai R&D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
| US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| CN101616671A (zh) * | 2007-01-19 | 2009-12-30 | 卫材R&D管理有限公司 | 胰腺癌治疗用组合物 |
| WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
| TW200925152A (en) * | 2007-08-23 | 2009-06-16 | Plus Chemicals S A | Processes for the preparation of crystalline forms A, B and pure crystalline form a of erlotinib HCL |
| TWI436775B (zh) * | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
| KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
| US8436044B2 (en) | 2008-01-28 | 2013-05-07 | Nanocarrier Co., Ltd. | Pharmaceutical composition or combination drug |
| MX2010008187A (es) * | 2008-01-29 | 2010-08-10 | Eisai R&D Man Co Ltd | Uso combinado de inhibidor de angiogenesis y taxano. |
| WO2010107960A1 (en) * | 2009-03-17 | 2010-09-23 | Brody Jonathan R | Methods for assessing the efficacy of gemcitabine or ara-c treatment of cancer using human antigen r levels |
| TH121482A (th) | 2009-08-19 | 2013-02-28 | นางสาวปัณณพัฒน์ เหลืองธาตุทอง | องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน |
| CA2713610C (en) * | 2009-10-02 | 2019-08-20 | Monash University | Ectopic pregnancy treatment |
| AU2011270165B2 (en) | 2010-06-25 | 2015-12-24 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| CL2011000273A1 (es) | 2011-02-08 | 2011-06-17 | Univ Pontificia Catolica Chile | Uso de un inhibidor de la enzima fosfohidrolasa de acido fosfatidico (pap) o combinacion de inhibidores, en que el inhibidor es d(+) propranolol, y la combinacion es mezcla racemica de propranolol o d(+) propranolol junto con desipramina, para preparar un medicamento util en el tratamiento del cancer. |
| WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| WO2013006230A2 (en) * | 2011-07-01 | 2013-01-10 | Fox Chase Cancer Center | Combined inhibition of the vitamin d receptor and dna replication in the treatment of cancer |
| EP2773340B1 (en) * | 2011-11-04 | 2020-01-08 | Myron R. Szewczuk | Use of neu1 sialidase inhibitors in the treatment of cancer |
| RU2015115397A (ru) | 2012-12-21 | 2017-01-25 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Аморфная форма производного хинолина и способ его получения |
| ES2687968T3 (es) | 2013-05-14 | 2018-10-30 | Eisai R&D Management Co., Ltd. | Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib |
| WO2015166986A1 (ja) | 2014-04-30 | 2015-11-05 | 富士フイルム株式会社 | リポソーム組成物及びその製造方法 |
| KR20230043234A (ko) | 2014-08-28 | 2023-03-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| US9889141B2 (en) | 2014-10-14 | 2018-02-13 | Institute For Cancer Research | Combined inhibition of the vitamin D receptor and poly(ADP) ribose polymerase (PARP) in the treatment of cancer |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| CA2994925C (en) | 2015-08-20 | 2023-08-29 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| BR112019023064A2 (pt) | 2017-05-16 | 2020-06-09 | Eisai R&D Man Co Ltd | tratamento de carcinoma hepatocelular |
| RU2019140001A (ru) * | 2017-05-18 | 2021-06-18 | Ту Ту Биотек Лтд. | Способ сенсибилизации раковых клеток к противораковой терапии |
| JP7364561B2 (ja) * | 2018-06-20 | 2023-10-18 | 富士フイルム株式会社 | ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬 |
| CN111773388B (zh) * | 2019-04-04 | 2023-07-18 | 上海奥奇医药科技有限公司 | A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030108545A1 (en) * | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| HK1047236A1 (zh) * | 1999-05-14 | 2003-02-14 | Imclone Llc | 用表皮生长因子受体拮抗剂治疗难治的人肿瘤 |
| UA74803C2 (uk) * | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| JP2004529315A (ja) * | 2000-11-03 | 2004-09-24 | ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム | 抗癌処置の効力を検出するための方法 |
| AU2002239486A1 (en) * | 2000-12-08 | 2002-06-18 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
| PA8578001A1 (es) * | 2002-08-07 | 2004-05-07 | Warner Lambert Co | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas |
| TW200501960A (en) * | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
-
2005
- 2005-05-27 CN CNA2005800179097A patent/CN1960732A/zh active Pending
- 2005-05-27 BR BRPI0511760-7A patent/BRPI0511760A/pt not_active IP Right Cessation
- 2005-05-27 WO PCT/EP2005/005735 patent/WO2005117887A1/en not_active Ceased
- 2005-05-27 CA CA002567836A patent/CA2567836A1/en not_active Abandoned
- 2005-05-27 AU AU2005249205A patent/AU2005249205A1/en not_active Abandoned
- 2005-05-27 KR KR1020067025451A patent/KR100986945B1/ko not_active Expired - Fee Related
- 2005-05-27 JP JP2007513817A patent/JP2008501652A/ja active Pending
- 2005-05-27 NZ NZ551406A patent/NZ551406A/en unknown
- 2005-05-27 MX MXPA06014015A patent/MXPA06014015A/es active IP Right Grant
- 2005-05-27 EP EP05753110A patent/EP1755608A1/en not_active Withdrawn
- 2005-05-27 RU RU2006146619/15A patent/RU2006146619A/ru unknown
- 2005-06-03 US US11/144,952 patent/US20050272688A1/en not_active Abandoned
-
2006
- 2006-11-23 IL IL179525A patent/IL179525A0/en unknown
- 2006-11-30 ZA ZA200610049A patent/ZA200610049B/en unknown
- 2006-12-28 NO NO20066056A patent/NO20066056L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005249205A1 (en) | 2005-12-15 |
| RU2006146619A (ru) | 2008-07-20 |
| IL179525A0 (en) | 2007-07-04 |
| BRPI0511760A (pt) | 2008-01-08 |
| CA2567836A1 (en) | 2005-12-15 |
| KR20070029736A (ko) | 2007-03-14 |
| MXPA06014015A (es) | 2007-02-08 |
| JP2008501652A (ja) | 2008-01-24 |
| KR100986945B1 (ko) | 2010-10-12 |
| US20050272688A1 (en) | 2005-12-08 |
| NZ551406A (en) | 2010-03-26 |
| ZA200610049B (en) | 2008-06-25 |
| CN1960732A (zh) | 2007-05-09 |
| EP1755608A1 (en) | 2007-02-28 |
| WO2005117887A1 (en) | 2005-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20066056L (no) | Behandling med Gemcitabin og en EGFR-inhibitor | |
| NO20066054L (no) | behandling med cisplatin og en EGFR-inhibitor | |
| Singh et al. | Mechanisms of temozolomide resistance in glioblastoma-a comprehensive review | |
| WO2007075554A3 (en) | Combination of igfr inhibitor and anti-cancer agent | |
| WO2007106503A3 (en) | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors | |
| Manic et al. | Chloroquine and hydroxychloroquine for cancer therapy | |
| WO2020093006A8 (en) | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| MX2022012178A (es) | Compuestos, composiciones farmaceuticas y metodos para la preparacion de compuestos y para su uso. | |
| EA202190630A1 (ru) | Способы комбинированной терапии | |
| EP4552631A3 (en) | Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer | |
| NO20070514L (no) | Pyrrolotriazin kinase inhibitorer | |
| WO2006110175A3 (en) | Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor | |
| NO20053782L (no) | Behandling av kreft med 2-deoksyglukose | |
| WO2009008992A3 (en) | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2 | |
| NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
| NO20050528L (no) | Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft | |
| BRPI0622054B8 (pt) | composto e composição farmacêutica | |
| NO20092604L (no) | VEGF-spesifikke antagonister antistoff eller antigenbindende fragmenter derav for anvendelse i en fremgangsmåte for å redusere eller forhindre forekomst av kreft hos et individ som aldri har hatt klinisk detekterbar kreft, samt anvendelse derav for fremstilling av et medikament. | |
| WO2019197605A3 (en) | Drug combinations for use in the treatment of ras-mutant cancer | |
| CY1109681T1 (el) | Υποκατεστημενα παραγωγα κιναζολινης ως αναστολεις των κινασων aurora | |
| PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor | |
| PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
| WO2006110176A3 (en) | Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor | |
| NO20066080L (no) | Behandling med irinotecan (CPT-11) og en AGFR-inhibitor | |
| RU2008148597A (ru) | Фармацевтические комбинации |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |